Cycl

Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine

- Phase II Results Published in the Journal of Clinical Oncology - NEW YORK, July 06, 2007 /PRNewswire-FirstCall/ -- Results from aPhase II study - which will be published in the August 10, 2007issue of the Journal of Clinical Oncology (JCO) and are nowavailable as an Early Release Article at <a target="_blank" href="http://www.jco.org/">www.jco.org - demonstrate thatixabepilone, a Br...

Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies

BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Jun 28, 2007 - CyclacelPharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) announced todaythe results from two Phase II non-randomized studies of seliciclibfixed dose combinations. In one study seliciclib was given incombination with gemcitabine and cisplatin and in another withdocetaxel in patients with advanced non-small cell lung cancer(NSCLC).<p...

Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer

WAILEA, Hawaii and SUNNYVALE, Calif., June 27, 2007/PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announcedpreliminary results from two open-label, multi-center Phase 2clinical trials supporting the potential use of Xcytrin(R)(motexafin gadolinium) Injection, the company's lead productcandidate, in combination with Alimta(R) (pemetrexed) and incombination with Taxotere(R) (docetaxel...

Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes

Data Also Support Drug's Efficacy at Improving Glycemic Control andReducing Diabetic Cardiovascular Complications CHICAGO, Ill., June 23, 2007 /PRNewswire/ -- VeroScience, LLC,in conjunction with its commercialization partner S2 Therapeutics,Inc., reported today the results of its Phase IIIb clinical trialsupporting the overall and cardiovascular safety of Cycloset(TM) (Aquick release for...

VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions

TIVERTON, R.I., June 18, 2007 /PRNewswire/ -- VeroScience, LLC,a privately held biotechnology and healthcare product developmentcompany, announced today that its late-breaking abstract has beenaccepted as a poster presentation at the 67th Scientific Sessionsof the American Diabetes Association in Chicago, Ill. The abstract,entitled, "Effects of Timed Cycloset(TM) (A Quick ReleaseFormulat...

New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel

22 US Oncology Affiliated Physicians Participate in ASCOProceedings HOUSTON, June 04, 2007 /PRNewswire/ -- A leading cancerresearcher affiliated with the US Oncology Research Networkpresented findings from a randomized, multicenter phase III trialthat compared the disease-free survival (DFS) obtained with tworegimens of adjuvant therapy for patients with high-risk breastcancer. Th...

Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer

- Data Support Rationale for Comprehensive Ongoing Phase 2 Programas Combination Agent with Standard Chemotherapies and Pivotal LungCancer Trial Scheduled to Begin Early Next Year - CHICAGO and SUNNYVALE, Calif. June 01, 2007/PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announcedpromising preliminary results from an open-label Phase 2 clinicaltrial of Xcytrin(R) (motexafin gadoliniu...

LifeCycle Pharma Announces Positive Phase I Clinical Results for its Transplantation Product Candidate, LCP-Tacro

Heads into US Phase II Clinical Trials for Organ Transplantation HORSHOLM, Denmark, May 31, 2007 /PRNewswire-FirstCall/ --LifeCycle Pharma announces positive Phase I clinical results forits transplantation product candidate, LCP-Tacro - Heads into USPhase II clinical trials for organ transplantation. Today LifeCycle Pharma A/S (OMX:LCP) announces positive resultsfrom its Phase I cli...

Cyclacel Pharmaceuticals to Report Sapacitabine Phase I Study Results at the American Society of Clinical Oncology Annual Meeting

BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--May 24, 2007 - CyclacelPharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) announced todaythat it will report results from a Phase I pharmacologic trial ofsapacitabine (CYC682), a novel orally-available nucleoside analog,in patients with advanced leukemias or myelodysplastic syndromes(MDS), at the American Society of Clinical Oncology's (ASCO) Annual...

Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting

SUNNYVALE, Calif., May 23, 2007 /PRNewswire-FirstCall/ --Pharmacyclics, Inc. announced today multiple presentations and apublished abstract regarding Xcytrin(R) (motexafin gadolinium)Injection, including an oral presentation of Phase 3 SMART (Studyof Neurologic Progression with Motexafin Gadolinium And RadiationTherapy) trial data. The presentations and publications are part ofthe procee...

Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis

KANSAS CITY, Mo.--(BUSINESS WIRE)--May 4, 2007 - New data from arandomized, double-blind study showed that a combination ofCOPAXONE(R) (glatiramer acetate injection) along with the oralantibiotic minocycline reduced T1 Gadolinium (Gd)-enhancing lesionsof the brain by 63 percent (p=0.08) in patients with activerelapsing-remitting multiple sclerosis (RRMS), as measured bymagnetic resonance im...

Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis

Treatment with Copaxone Plus Minocycline Showed SubstantialReduction of Disease Activity in Patients with ActiveRelapsing-Remitting Multiple Sclerosis Combination Treatment With Antibiotic Further Reduced BrainLesions and Was Well Tolerated KANSAS CITY, Mo, May 4, 2007 - New data from a randomized,double-blind study showed that a combination of Copaxone(glatiramer acetate in...

Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory Dose Doxycycline for the Treatment of Rosacea

NEWTOWN, Pa.--(BUSINESS WIRE)--Apr 30, 2007 - CollaGenexPharmaceuticals, Inc. (NASDAQ:CGPI) today announced that a newreport in the May 2007 issue of the Journal of the American Academyof Dermatology evaluating two randomized phase III clinical trials,demonstrated the efficacy and safety of anti-inflammatory dosedoxycycline (Oracea(R), 40-mg doxycycline, USP capsules) for thetreatment of ro...

Clinical Update - Debio 025 Cyclophilin Inhibitor for the Treatment of HCV

A Unique Viral Kinetics Profile LAUSANNE, Switzerland, April 19, 2007 /PRNewswire/ -- DebiopharmGroup (Debiopharm), a global independent biopharmaceuticaldevelopment specialist in oncology and serious medical conditions,presented additional results of a previous phase Ib, 15 day studywith cyclophilin (Cyp) inhibitor Debio 025 in HIV/HCV (hepatitis Cvirus) co-infected patients. The data we...

Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Bruton's Tyrosine Kinase Inhibitors

SUNNYVALE, Calif. and LOS ANGELES, April 18, 2007/PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announced datafrom two preclinical studies, one identifying a functionalbiomarker for its novel histone deacetylase (HDAC) inhibitor andanother demonstrating preclinical anti-tumor activity with itsBruton's tyrosine kinase (BTK) inhibitor compounds. The data werepresented at the American...

Arrowhead Subsidiaries Insert & Calando Present Data on Cyclosert Drug Delivery System at AACR Meeting

Novel Systems May Provide Cancer Patients With Improved Potentialto Battle Their Disease PASADENA, Calif., April 16, 2007 /PRNewswire-FirstCall/ --Arrowhead Research Corporation announced today that two of itsmajority-owned subsidiaries, Insert Therapeutics Inc. and CalandoPharmaceuticals Inc., are presenting data at the 2007 AmericanAssociation for Cancer Research (AACR) Annual Meeting....

Poster on Cyclosert Drug Delivery Presented at AACR Meeting

Novel System May Provide Cancer Patients With Improved Potential toBattle Their Disease PASADENA, Calif., April 16, 2007 /PRNewswire/ -- InsertTherapeutics, Inc., a majority-owned subsidiary of ArrowheadResearch Corporation announced today its novel delivery systemcalled Cyclosert(TM) will be featured in a poster presentation atthe 2007 American Association for Cancer Research (AACR) Annu...

Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Bruton's Tyrosine Kinase Inhibitor Compounds

SUNNYVALE, Calif., April 11, 2007 /PRNewswire-FirstCall/ --Pharmacyclics, Inc. announced today multiple presentationsregarding its novel histone deacetylase (HDAC) inhibitor andBruton's tyrosine kinase inhibitor compounds. The presentationswill take place at the American Association for Cancer Research(AACR) 2007 Annual Meeting being held April 14-18, 2007, at the LosAngeles Convention C...

Cyclacel Pharmaceuticals to Present Preclinical Data on Sapacitabine and Seliciclib at AACR

BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Apr 11, 2007 - CyclacelPharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) announcedtoday that scientists from the company will present results of twopreclinical studies with sapacitabine and seliciclib, the company'smost advanced drug candidates in clinical development. The resultswill be reported in two poster presentations during the upcomingAnnu...